Interleukin-34 cancels anti-tumor immunity by PARP inhibitor

OBJECTIVE: Breast cancer susceptibility gene 1 (BRCA1)-associated ovarian cancer patients have been treated with A poly (ADP-ribose) polymerase (PARP) inhibitor, extending the progression-free survival; however, they finally acquire therapeutic resistance. Interleukin (IL)-34 has been reported as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Takayoshi, Kajihara, Nabeel, Hama, Naoki, Kobayashi, Takuto, Otsuka, Ryo, Han, Nanumi, Wada, Haruka, Hasegawa, Yoshinori, Suzuki, Nao, Seino, Ken-ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157335/
https://www.ncbi.nlm.nih.gov/pubmed/36603850
http://dx.doi.org/10.3802/jgo.2023.34.e25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157335/
https://www.ncbi.nlm.nih.gov/pubmed/36603850
http://dx.doi.org/10.3802/jgo.2023.34.e25

Ejemplares similares